These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33856094)

  • 1. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
    Klein O; Brown WA; Saxon S; Haydon A
    Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
    Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
    J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
    Klein O; Senko C; Carlino MS; Markman B; Jackett L; Gao B; Lum C; Kee D; Behren A; Palmer J; Cebon J
    Oncoimmunology; 2021 Apr; 10(1):1908771. PubMed ID: 33889439
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
    Gim G; Kim Y; Park Y; Kim MJ; Nam M; Yang W; Duarte SE; Jung CM; Vagia E; Viveiros P; Chae YK
    Oncologist; 2022 Jul; 27(7):525-531. PubMed ID: 35640145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report.
    Hsieh-Wong J; Liu J; Huynh J; Parikh M; Kim E; Gong J; Halabi W; Siricilla M; Mitra A; Toomey K; Cho M
    J Gastrointest Oncol; 2022 Jun; 13(3):1473-1480. PubMed ID: 35837187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.
    Zhou KI; Hanks BA; Strickler JH
    J Gastrointest Cancer; 2024 Jun; 55(2):483-496. PubMed ID: 38133871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
    Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
    Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
    Rotte A
    J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
    Kanani A; Veen T; Søreide K
    Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
    Cao X; Luo J; Zhao B; Fu H; Kang W
    Front Immunol; 2022; 13():1036181. PubMed ID: 36544760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.